glp 1 non diabetic GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Non-Diabetic GLP-1 Use: Weight Loss

A recent Survey of Ophthalmology review synthesized findings from cardiovascular outcomes trials, retrospective database analyses, meta-analyses and preclinical studies involving semaglutide, liraglutide, dulaglutide and related agents across six ocular conditions: diabetic retinopathy (DR), glaucoma, nonarteritic anterior ischemic optic neuropathy (NAION), age-related macular degeneration (AMD), idiopathic intracranial hypertension (IIH) and dry eye disease (DED)

OSA and cardiovascular indications still covered with PA

(2024, January 10)

Boost energy, metabolism, and support weight loss with Lipo B12 Injections at Aesthetic Chemistry Medspa

Thats where BPC 157 comes in

Here are 8 potential reasons why not to prescribe Lixisenatide: 1- this is only one small study and only one dose was tested, 2- Lixisenatide is not currently available at pharmacies, 3- the weight loss associated with this GLP-1 is not desirable in many cases of Parkinsons disease where weight loss is an issue, 4- non-motor outcomes did not change as in other trials, and this will need to be better explained